News
December 21, 2022

Digital Detection of Dementia: Using AI to identify undiagnosed dementia

Digital Detection of Dementia: Using AI to identify undiagnosed dementia

Researchers present protocol for Indianapolis and Miami trials

INDIANAPOLIS — Rising to meet the formidable challenge of the timely diagnosis of dementia, research scientists from Regenstrief Institute, IUPUI and the medical schools of Indiana University and University of Miami are conducting the Digital Detection of Dementia study, a real-world evaluation of the use of an artificial intelligence (AI) tool they developed for early identification of Alzheimer’s disease and related dementias in primary care, the setting where most adults receive healthcare. Individuals identified as cognitively impaired will be referred for diagnostic services.

The AI tool, called a passive digital marker, is a machine learning algorithm the researchers developed, trained and tested. The tool uses natural language processing to cull unstructured information in combination with structured data from a patient’s electronic health record. These could include mention of memory issues, a notation of vascular concerns, comorbid conditions or other factors potentially linked to dementia.

“Between 50 to 80 percent of dementia cases are unrecognized by the healthcare system in the U.S. And, if you include patients living with mild cognitive impairment, that number might actually climb to higher than 80 percent of cases that are not recognized,” said Regenstrief Institute and Indiana University School of Medicine faculty member Malaz Boustani, M.D., MPH, senior author of the Digital Detection of Dementia study protocol paper, published in the peer-reviewed journal Trials. “In this new study we are evaluating the practical use of our tool when used alone and when used with an accompanying patient-reported outcomes survey.

“Unfortunately, the lay public believe there’s nothing you can do if you find out you or a family member has Alzheimer’s disease, but that is not true. Over the past 20 years we have developed, validated and have been operating a comprehensive collaborative care model for dementia that reduces the disease burden for the patient, reduces caregiver stress and reduces inappropriate hospitalizations, keeping people living at home longer and lowering overall costs to them and to the healthcare system,” he said.

Few primary care practices are designed for the timely detection of Alzheimer’s disease. The limited time that primary care clinicians have to spend with patients, the need to focus on the health problems which brought the patient to the clinic, as well as the stigma of dementia are the major reasons for lack of recognition of the condition, according to Dr. Boustani. In addition, he notes, there is no demand from the public for dementia diagnoses, most likely driven by the stigma of dementia, lack of public knowledge about benefits of early recognition of Alzheimer’s, and issues related to health insurance coverage.

The first aspect of the Digital Detection of Dementia study is a clinical trial, already underway in Indianapolis enrolling patients seen in primary care clinics at federally qualified health centers affiliated with Eskenazi Health. The participants in this trial are expected to be predominantly people who are Black and reside in urban areas. The second clinical trial of the study commences early in 2023 in Miami, Florida, at University of Miami primary care clinics. The participants are expected to be predominantly Hispanic and include a high percentage of rural residents.

Each trial is the same and has three arms: (1) usual primary care approach; (2) the specially designed passive digital marker relying on artificial intelligence; and (3) the novel passive digital marker plus a specially designed patient reported outcomes survey.

Patients in all three arms will be followed for two consecutive years to determine how many new cases of Alzheimer’s disease were recognized and documented in patients’ electronic health records.

The 7,200 anticipated study participants (3,600 in Indiana and 3,600 in Florida) must be 65 years old or older, have had at least one visit to a primary care practice within the past year and be able to communicate in English or Spanish. Electronic health record data from at least the past three years must be available to be enrolled in the study. Individuals residing in a nursing home or with serious mental illness are not eligible.

“Passive digital markers are developed by using data from electronic health records,” said Zina Ben Miled, PhD, a Regenstrief Institute affiliated scientist and an IUPUI associate professor of electrical and computer engineering, who developed the passive digital marker tool along with Dr. Boustani. “The benefit of this approach is that the information has already been collected and requires no extra effort from the patient or the provider. Through machine learning algorithms and natural language processing, we can use this data to identify people who may be at risk for Alzheimer’s disease without the need for invasive and costly tests.”

“Through this project, we hope to prove that these approaches can be successfully implemented in the real world, leading to benefits for both patients and their families,” said cognitive neurologist James E. Galvin, M.D, MPH, a professor of neurology at the University of Miami’s Miller School of Medicine. “Combining a patient-reported outcome with a passive digital marker is an innovative and highly sensitive way to detect mild cognitive impairment, Alzheimer’s disease and related disorders, yet low burden to patients and clinicians for ease of use.” Dr. Galvin developed the patient reported outcomes tool.

Both the passive digital marker tool and the patient-reported outcomes tool are low cost. The Digital Detection of Dementia study will confirm their suitability for use in primary care practices as well as their scalability.

It is estimated that the prevalence of dementia in primary care in the U.S. is about 6 percent of patients but only 2 percent of patients are recognized by the healthcare system as having the condition. The researchers believe use of their passive digital marker, possibly in tandem with the patient-reported outcomes tool, will potentially double the number of cases identified, improving the lives of more individuals living with dementia and their caregivers.

“We are not just recognizing patients with cognitive impairment and saying, ‘See you later.’ We are also providing computerized decision support to the primary care clinician that will help them refer these patients for confirmatory dementia screening. If the screening is positive, they can receive care based on our successful, evidence-based collaborative dementia care model,” said Dr. Boustani

“Digital detection of dementia (D3): a study protocol for a pragmatic cluster-randomized trial examining the application of patient-reported outcomes and passive clinical decision support systems,” is supported by a five-year grant from the National Institutes of Health’s National Institute on Aging. Authors, in addition to Drs. Boustani, Ben Miled and Galvin are Randall W. Grout, M.D., M.S., Paul Richard Dexter, M.D., and Nicole Fowler, PhD, all of Regenstrief Institute and IU School of Medicine; Arthur Owora, PhD, IU Bloomington School of Public Health; and joint first authors Michael J. Kleiman, PhD, University of Miami, and Abbi D. Plewes, IU School of Medicine.

About Malaz Boustani, M.D., MPH

In addition to his role as a research scientist at Regenstrief Institute, Malaz Boustani, M.D., MPH, is the founding director of the Center for Health Innovation and Implementation Science. He is a professor and the Richard M. Fairbanks Professor in Aging Research at Indiana University School of Medicine. Dr. Boustani is also director of care innovation at Eskenazi Health.

About Zina Ben Miled, PhD, M.S.

Zina Ben Miled, PhD, M.S., is an associate professor of electrical and computer engineering in the Purdue School of Engineering and Technology at IUPUI and a research scientist in the Center for Health Innovation and Implementation Science. She is also a Regenstrief Institute affiliate scientist. 

About James E. Galvin, M.D., MPH

James E. Galvin, M.D., MPH, is a professor of neurology at the University of Miami Miller School of Medicine. He is the founding director of the Comprehensive Center for Brain Health and chief of the division of cognitive neurology in the Department of Neurology.

About Regenstrief Institute

Founded in 1969 in Indianapolis, the Regenstrief Institute is a local, national and global leader dedicated to a world where better information empowers people to end disease and realize true health. A key research partner to Indiana University, Regenstrief and its research scientists are responsible for a growing number of major healthcare innovations and studies. Examples range from the development of global health information technology standards that enable the use and interoperability of electronic health records to improving patient-physician communications, to creating models of care that inform practice and improve the lives of patients around the globe.

Sam Regenstrief, a nationally successful entrepreneur from Connersville, Indiana, founded the institute with the goal of making healthcare more efficient and accessible for everyone. His vision continues to guide the institute’s research mission.

About IU School of Medicine

IU School of Medicine is the largest medical school in the U.S. and is annually ranked among the top medical schools in the nation by U.S. News & World Report. The school offers high-quality medical education, access to leading medical research and rich campus life in nine Indiana cities, including rural and urban locations consistently recognized for livability.

About IUPUI

As Indiana’s premier urban public research university, IUPUI believes in the power of transformation. It is committed to providing educational opportunities that transform the lives of students, the community and the changing world. It offers more than 450 undergraduate, graduate and professional programs from Indiana University and Purdue University.

About University of Miami Miller School of Medicine

The University of Miami Miller School of Medicine is an innovative institution that empowers students and trainees to transform lives and inspires them to serve the global community. Founded in 1952, it was Florida’s first medical school. It now includes 21 clinical departments, 6 basic science departments, 45 centers and institutes, and more than 1,400 faculty members. South Florida’s cultural diversity makes it a medical training ground of unmatched opportunity.

Related News

photo of elderly Asian couple and graph showing that dementia prevelance doubles every five years after age 65

Dementia complicates cancer care, increasing risk of poorer clinical outcome and patient experience

Review authors make recommendations for treatment of cancer in patients with dementia Pre-existing dementia complicates cancer care and increases

Blood sugar monitoring devices pose wearability and use problems for older adults with diabetes and caregivers

A study conducted by Regenstrief Institute research scientists to examine the use, by older adults with Type 1 or

word art image of the effect on health outcomes where ageism and racism intersect

Expanding the national dialogue on healthcare to include the intersection of structural racism and ageism

Advocating for and supporting health equity Regenstrief Institute Research Scientist Kathleen Unroe, M.D., MHA, is a co-author of a

Dr. Shaun Grannis on the need for standardization in U.S. patient data matching

Dr. Shaun Grannis on the need for standardization in U.S. patient data matching

Dr. Shaun Grannis discusses the need to standardize patient identity matching — the last “gaping hole” in the U.S.